Patents by Inventor Bryce C. Chackerian

Bryce C. Chackerian has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Malaria immunogen and methods for using same
    Patent number: 12121574
    Abstract: An immunogen useful for treating malaria generally includes an immunogenic carrier and an antigenic malaria circumsporozoite protein (CSP) peptide that includes the peptide NANPNVDPNANPNVD (SEQ ID NO:2) linked to the immunogenic carrier. The immunogen may be administered to a subject having or at risk of having malaria. Alternatively, the immunogen may be administered to an individual having or at risk of having Plasmodium falciparum blood stage parasitemia. In some cases, the immunogen can be administered in combination with another therapeutic agent for treating malaria of Plasmodium falciparum blood stage parasitemia.
    Type: Grant
    Filed: September 27, 2022
    Date of Patent: October 22, 2024
    Assignees: UNM RAINFOREST INNOVATIONS, THE JOHNS HOPKINS UNIVERSITY, VAXINE PTY LTD.
    Inventors: Bryce C. Chackerian, Fidel P. Zavala, David S. Peabody, Nikolai Petrovsky, Lucie Jelinkova
  • MALARIA IMMUNOGEN AND METHODS FOR USING SAME
    Publication number: 20230102159
    Abstract: An immunogen useful for treating malaria generally includes an immunogenic carrier and an antigenic malaria circumsporozoite protein (CSP) peptide that includes the peptide NANPNVDPNANPNVD (SEQ ID NO:2) linked to the immunogenic carrier. The immunogen may be administered to a subject having or at risk of having malaria. Alternatively, the immunogen may be administered to an individual having or at risk of having Plasmodium falciparum blood stage parasitemia. In some cases, the immunogen can be administered in combination with another therapeutic agent for treating malaria of Plasmodium falciparum blood stage parasitemia.
    Type: Application
    Filed: September 27, 2022
    Publication date: March 30, 2023
    Inventors: Bryce C. Chackerian, Fidel P. Zavala, David S. Peabody, Nikolai Petrovsky, Lucia Jelinkova
  • Immunogenic respiratory syncytial virus glycoprotein-containing VLPs and related compositions, constructs, and therapeutic methods
    Patent number: 9884107
    Abstract: The invention provides immunotherapeutic and prophylactic bacteriophage viral-like particle (VLPs) which are useful in the treatment and prevention of Respiratory Syncytial Virus (RSV) infections and related disorders, including bronchiolitis and viral pneumonia. Related compositions (e.g. vaccines), nucleic acid constructs, and therapeutic methods are also provided. VLPs and related compositions of the invention induce high titer antibody responses against RSV. VLPs, VLP-containing compositions, and therapeutic methods of the invention induce an immunogenic response against RSV infection, confer immunity against RSV infection, protect against RSV infection, and reduce the likelihood of infection by RSV infection.
    Type: Grant
    Filed: October 21, 2016
    Date of Patent: February 6, 2018
    Assignee: STC.UNM
    Inventors: Bryce C. Chackerian, David S. Peabody
  • IMMUNOGENIC RESPIRATORY SYNCYTIAL VIRUS GLYCOPROTEIN-CONTAINING VLPs AND RELATED COMPOSITIONS, CONSTRUCTS, AND THERAPEUTIC METHODS
    Publication number: 20170095550
    Abstract: The invention provides immunotherapeutic and prophylactic bacteriophage viral-like particle (VLPs) which are useful in the treatment and prevention of Respiratory Syncytial Virus (RSV) infections and related disorders, including bronchiolitis and viral pneumonia. Related compositions (e.g. vaccines), nucleic acid constructs, and therapeutic methods are also provided. VLPs and related compositions of the invention induce high titer antibody responses against RSV. VLPs, VLP-containing compositions, and therapeutic methods of the invention induce an immunogenic response against RSV infection, confer immunity against RSV infection, protect against RSV infection, and reduce the likelihood of infection by RSV infection.
    Type: Application
    Filed: October 21, 2016
    Publication date: April 6, 2017
    Inventors: Bryce C. Chackerian, David S. Peabody
  • Immunogenic respiratory syncytial virus glycoprotein-containing VLPs and related compositions, constructs, and therapeutic methods
    Patent number: 9511135
    Abstract: The invention provides immunotherapeutic and prophylactic bacteriophage viral-like particle (VLPs) which are useful in the treatment and prevention of Respiratory Syncytial Virus (RSV) infections and related disorders, including bronchiolitis and viral pneumonia. Related compositions (e.g. vaccines), nucleic acid constructs, and therapeutic methods are also provided. VLPs and related compositions of the invention induce high titer antibody responses against RSV. VLPs, VLP-containing compositions, and therapeutic methods of the invention induce an immunogenic response against RSV infection, confer immunity against RSV infection, protect against RSV infection, and reduce the likelihood of infection by RSV infection.
    Type: Grant
    Filed: September 13, 2011
    Date of Patent: December 6, 2016
    Assignee: STC.UNM
    Inventors: Bryce C. Chackerian, David S. Peabody
  • Immunogenic Respiratory Syncytial Virus Glycoprotein-Containing VLPs and Related Compositions, Constructs, and Therapeutic Methods
    Publication number: 20130302371
    Abstract: The invention provides immunotherapeutic and prophylactic bacteriophage viral-like particle (VLPs) which are useful in the treatment and prevention of Respiratory Syncytial Virus (RSV) infections and related disorders, including bronchiolitis and viral pneumonia. Related compositions (e.g. vaccines), nucleic acid constructs, and therapeutic methods are also provided. VLPs and related compositions of the invention induce high titer antibody responses against RSV. VLPs, VLP-containing compositions, and therapeutic methods of the invention induce an immunogenic response against RSV infection, confer immunity against RSV infection, protect against RSV infection, and reduce the likelihood of infection by RSV infection.
    Type: Application
    Filed: September 13, 2011
    Publication date: November 14, 2013
    Applicant: STC.UNM
    Inventors: Bryce C. Chackerian, David S. Peabody